semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Turner Syndrome Aortic Aneurysm Ischemic Heart Disease Hypertension Congenital Heart Defect with respect to individuals acting as controls Healthy age matched females  Contraindications for MRI Contraindications for CT Severe obesity Acute og Chronic disease with known or presumed significance with concern to outcomes of the study Previous or present malignant disease Clinically significant liver disease Mechanic or biological heart valves
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-18.0,  Turner Syndrome Turner syndrome with homogeneous 45,X karyotype Age between 8 and 18 years Somatic state compatible with the evaluation Functional language and IQ ≥ 80 for the transfer tests Informed consent signed by the holders of parental authority, the patient and the mother for her own participation (DNA collection) Affiliation to Social Security (beneficiary or assignee)  Additional condition associated with an autism spectrum disorder Turner syndrome not related to an homogeneous 45,X karyotype
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Osteoporosis Atypical Femoral Fracture postmenopausal women with osteoporosis who have been on bisphosphonate therapy for one year or more (all bisphosphonates will be included such as alendronate, risdedronate, ibandronate, or zoledronic acid) Patients will also be included if they are on glucocorticoids or other medications known to affect bone mineral metabolism as these are often found in patients with these types of fractures sustain an atypical subtrochanteric or diaphyseal femoral shaft fracture as defined by the the 2010 ASBMR task force. An atypical fracture must all of the following: (1) a location in the femur distal to lesser trochanter; (2) no trauma or minimal trauma as a fall; (3) transverse or short oblique configuration; (4) noncomminuted; and (5) complete fracture extends through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex. Patients who have an incomplete fracture can be included if they fall into the 2010 ASBMR task force definition  men children those who have had radiation therapy Paget's disease treatment with teriparatide for two year in the past metastatic bone disease active cancer hypercalcemia hyperparathyroidism metabolic disease other than osteoporosis
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Genetic Disorder Turner Syndrome Turner Syndrome Treatment with growth hormone Bone age minimum 12 years and maximum 14 years Clear signs of ovarian insufficiency Well documented growth rate during the last 12 months  Signs of spontaneous puberty Known or suspected hypersensitivity to trial product Acute or chronic liver disease Previous treatment with estrogen Undiagnosed abnormal genital bleeding Known thyroid diseases not adeadequately treated Porphyria
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Growth Hormone Deficiency therapeutic need according to the approved specific products characteristics (SPC)  contraindication according to the SPC
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Genetic Disorder Turner Syndrome Turner syndrome If age below 3 years, either body height below SD (standard deviation) with average growth velocity according to chronological age or body height below 0 SD with growth velocity below -1 SD according to chronological age If age above 3 years, body height below SD with average growth velocity according to chronological age Measured parental height available Written informed consent
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Idiopathic Short Stature Age greater than or equal to 5 years Pre-pubertal; testicular volume less than 4 milliliter (in males) and breast Stage 1 (in females) The official records of height (for example records measured in hospitals or schools) during previous 6 months or more preceding in the study (self-measurement of the height at home will not be considered as a valid record) Height less than or equal to 3rd percentile compared to same sex, same age Peak serum growth hormone (GH) greater than 10 microgram per liter (mcg/L) in GH stimulation test (results of peak serum GH greater than 10 mcg/L in GH stimulation test within 1 year can be used instead) Naive to GH therapy Normal birth weight (that is greater than or equal to 3rd percentile when compared to same sex) Normal thyroid function Normal karyotype in girls Written informed consent from parent/guardian  Puberty development (Tanner stage greater than or equal to 2) Skeletal dysplasia or abnormal body proportions Chronic systemic illness Dysmorphic syndrome Growth Hormone Deficiency Small for Gestational Age (SGA) Current medication for Attention deficit hyperactivity disorder (ADHD) or hyperactivity disorder Current medication with drugs that may influence secretion or action of growth hormone (such as estrogen, androgen, anabolic steroid, corticosteroid, thyroxine, aromatase inhibitors) Diabetes mellitus Kidney transplantation
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 9.0-17.0,  Obesity Insulin Resistance Gonadal Dysfunction Type 2 Diabetes BMI ≥ 95th percentile At least Tanner 2, but no more than Tanner 3 Age ≥ 9 years Absence of impaired glucose tolerance (IGT), impaired fasting glucose (IFG) or Type 2 diabetes mellitus (T2DM)  Presence of T2DM, IGT or IFG Any disorder or medication known to effect glucose tolerance Hypertension or hyperlipidemia requiring pharmacological intervention Weight >300lbs. due to limits of imaging tables Chronic illness
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Angina Heart Disease Age >18 years of age with stable angina pectoris or an anginal equivalent symptom (e.g. atypical chest discomfort, dyspnea, easy fatigue) AND 2. Mild, moderate or severe myocardial ischemia detected on nuclear perfusion imaging (exercise or pharmacologic SPECT or Rubidium PET), exercise stress echocardiography or stress cardiac MRI OR Documentation of obstructive coronary artery with at least one major coronary artery (left anterior descending, circumflex or right coronary artery) of at least 70% by either conventional or CT coronary angiography  Acute coronary syndrome including unstable angina or non ST elevation myocardial infarction within the last 60 days 2. ST-elevation myocardial infarction within 60 days 3. Equivocal myocardial ischemia on non-invasive testing or studies demonstrating reversible perfusion defects complicated by significant attenuation artifacts. 4. Recent PCI within the last 60 days 5. Recent CABG within the last 60 days 6. Inability to sign informed consent 7. Patients who have taken ranolazine within 30 days of screening 8. Patients taking strong CYP3A inhibitors e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir 9. Patients taking inducers of CYP3A e.g. rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort 10. Patients with liver cirrhosis or liver disease that is Grade B or C by the Child-Pugh Classification 11. Prior allergic reaction or intolerance to ranolazine 12. Patients with a history of inherited or acquired prolonged QT interval 13. Moderate to severe claustrophobia or previous inability to undergo an MRI exam 14. Patients with implanted pacemaker or internal cardiac defibrillator 15. Patients who have a metallic foreign body implants (metal silver in their eye, cochlear implants) or have an aneurysm clip in their brain 16. GFR < 30 ml/m2 17. Type 2 second degree heart block (Mobitz II) in the absence of functioning permanent pacemaker. 18. Sinus node dysfunction in the absence of functioning permanent pacemaker. 19. Patients taking dipyridamole therapy. 20. Active bronchospasm (active asthma or COPD with active wheezing. -
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-12.0,  Turner's Syndrome Diagnosed with Turner's Syndrome through chromosome analysis The chronological age: 2≤AGE≤12 The yearly growth rate should be less than 6cm; the bone age should be equal or less than 12; the height ≤ 10th percentile for the heights of their agemates Before the adolescence, Tuner stage I (breast) Normal thyroid function  Growth hormone was administered for 12 months or longer in the past Treated with estrogen or adrenal androgens for 12 months or longer in the past Malignancy, CNS Trauma, Psychiatric Disorder
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Ductal Carcinoma In Situ Invasive Breast Cancer confirmed histological diagnosis of breast carcinoma or ductal carcinoma in situ (DCIS) treated with BCT no indication for treatment of regional LN Women with a bra size of 40 inches or greater, or a pre-surgery cup size of D or greater  Regional Lymph Node XRT indicated Bilateral breast cancer unhealed wound (skin not closed and/or infection) previous XRT to the same breast unable to lie prone presence of active connective tissue disease pregnancy unacceptable heart exposure (as measured by > 10% of the heart receiving 50% of the prescribed dose, i.e. V25Gy > 10%) adequate coverage of postoperative tumour bed not technically possible
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-20.0,  Down Syndrome Subclinical Hypothyroidism Males and females, ages 8 years Diagnosis of Down syndrome Subclinical hypothyroidism: TSH level between 5 mIU/L, normal T4 Parental/guardian permission (informed consent) and if appropriate, child assent Females who are at least 11 years of age or who are menarchal must have a negative urine/serum pregnancy test Committed to adherence to levothyroxine treatment and study completion  Pregnancy Type 1/Type 2 diabetes Chronic medical conditions or medication use that can affect growth, nutrition, blood glucose, insulin secretion, or thyroid function (such as lithium or certain seizure medications) Current use of levothyroxine or anti-thyroid hormone Cyanotic congenital heart disease, or pulmonary hypertension (as described by last echo report in subjects with CHD), or congenital heart disease considered medically unstable by the study cardiologists
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Disorder of Sex Development Intersex Conditions Congenital Adrenal Hyperplasia Hypospadias Must be a parent/caregiver of a patient who is newborn through 5 years old (i.e., 5.9 yrs) Patient clinical diagnosis of ambiguous genitalia (eg, 46,XX,Prader 2+; proximal hypospadias with uni/bilateral undescended testes) or sex chromosomes discordant with genital phenotype Condition must be newly ascertained where decisions regarding surgical procedures (internal or external genitalia), diagnostic testing, and/or other aspects of clinical management have yet to be made  Turner syndrome, Klinefelter syndrome, bladder or cloacal exstrophy
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 1.5-17.0,  Autistic Disorder Developmental Disabilities for autism participants Children between the ages of 1.6 and 17.11 years of age Males and females Diagnosis of autism based on DSM-IV-TR an expert clinical evaluation, and ADOS or ADI-R if needed Receiving or will receive a parent delivered intervention to alleviate symptoms related to their diagnosis of autistic disorder Have a care provider that will reliably bring subjects to their chosen intervention and clinic visits, and is trustworthy to provide accurate accounts of services provided to the subject for developmentally delayed participants Will have an age range between 1.6 and 17.11 years of age Males or females Diagnosis of a developmental delay or disorder based on DSM-IV-TR, ICD-10, and an expert clinical evaluation Have historical evidence of significant abnormal developmental milestones as determined by neurological history  for autism participants Is medically unstable (e.g., more than one seizure a month) Have a medical diagnosis that causes autism like symptomology (e.g., Fragile X, Down syndrome, Angelman's syndrome, tuberous sclerosis, Rett's disorder) for developmentally delayed subjects Is medically unstable (e.g., more than one seizure a month) Has a diagnosis of ASD
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Chronic Myelogenous Leukemia Short Stature CML patients on Imatinib therapy for more than 6 months and in remission will be included in the study if there is 1. severe short stature (height SDS <-3 SD) 2. severe growth deceleration (height velocity <-2 SD over 12 months) 3. Height <-2 SD and height velocity <-1.0 SD over 12 months 4. Height <-1.5 SD and height velocity <-1.5 SD over 2 years  Patients with coexisting systemic illness(e.g. kidney disease, liver disease, celiac disease). 2. Patients of CML not receiving Imatinib therapy as prescribed (poor compliance)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypothyroidism Suspected hypothyroidism subject Willing to comply with the trial protocol Signed informed consent document  Menstrual period, bleeding hemorrhoids, hematuria Drinking or taking aspirin within 48 hours Subjects with partially or completely restricted consciousness and behavioral ability, who do not have independent decision-making ability Subjects who are unwilling or unable to complete the trial Subjects who do not sign informed consent form
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 6.0-16.0,  Short Stature Obesity, Childhood Children evaluated for short stature Normal weight \ overweight \ obesity  Known GH deficiency
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-8.0,  Precocious Puberty Excess; Development, Breast Clinical diagnosis of precocious puberty or premature thelarche 6 year old girls at time of diagnosis for the medical record review 8 year old girls at baseline for the re-examination